Article
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
Cancer discovery - 1 Jan 2016
Infarinato Nicole R, Park Jin H, Krytska Kateryna, Ryles Hannah T, Sano Renata, Szigety Katherine M, Li Yimei, Zou Helen Y, Lee Nathan V, Smeal Tod, Lemmon Mark A, Mossé Yael P
Abstract excerpt
UNLABELLED: Neuroblastomas harboring activating point mutations in anaplastic lymphoma kinase (ALK) are differentially sensitive to the ALK inhibitor crizotinib, with certain mutations conferring intrinsic crizotinib resistance. To overcome this clinical obstacle, our goal was to identify inhibitors with improved potency that can target intractable ALK variants such as F1174L. We find that PF-06463922 has high...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.